GIG HARBOR, Wash., June 25, 2015 /PRNewswire-USNewswire/ --
Metagenics Healthcare Institute for Clinical Nutrition announced exclusive licensing rights to the targeted probiotic, Lactobacillus salivarius subsp. salivarius UCC118 from Alimentary Health and University College Cork, Cork, Ireland. Probiotics are live microorganisms found naturally in the body and UCC118 is a specialized probiotic also known as a ‘precision biotic’ as it offers a targeted solution to support intestinal function including support of intestinal permeability.
Mounting scientific and clinical evidence, as seen in the current New York Times, is revealing specific probiotics influence targeted aspects of health outcomes ranging from influence of metabolic conditions to the gut brain axis including mood and anxiety. The human gut is host to over 100 trillion bacteria, known as the microbiome. Selective probiotics have been identified, that target and precisely affect gut function and barrier protection. This may include altering microbiome composition to alleviate dysbiosisor gut dysfunction. A common dysbiosis is known as “Leaky Gut” or “Intestinal Hyperpermeability” where the intestinal lining no longer maintain its integrity and allows unregulated passage of harmful toxins, antigens and bacteria across the intestinal barrier. This ‘leaking’ may be a key factor in intestinal inflammation and the pathogenesis of various chronic diseases including inflammatory bowel disease. John Troup, PhD, CSO of Metagenics commented, “Our commitment to clinical research in digestive health and the development of ‘precision biotics’ is an important step toward providing practitioners and patients with more selective and effective nutritional therapy solutions,” Troup went on to say, “Our licensing of these new probiotics introduces the next generation and advancement of technologies for digestive health maintenance and the broad range of influence that the gut has on health status.”
Over the next three years clinical research with investigators including Mark Lyte, PhD and John Cryan, PhD will be part of the Metagenics research program to develop new probiotics. The Human Microbiome Project, begun in 2007, led emerging knowledge by recognizing many health conditions influenced by specific microflora and identifying microbial “fingerprints” associated with various diseases. It’s estimated over 3000 genomes will be sequenced through the Project. As Troup notes, “Targeted therapy is the future of clinical practice. By identifying specific probiotic strains for specific indications will allow for improved outcomes in chronic diseases that have, till now, been elusive.”
Logo - http://photos.prnewswire.com/prnh/20150605/221247LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/metagenics-inc-announces-partnership-for-precision-biotic-research--product-use-300104517.html
SOURCE Metagenics Healthcare Institute for Clinical Nutrition
Help employers find you! Check out all the jobs and post your resume.
